Dynamic Contrast-enhanced CT to Assess Metabolic Response in Patients with Advanced Non-small Cell Lung Cancer and Stable Disease After Chemotherapy or Chemoradiotherapy

Overview

Journal Eur Radiol

Specialty Radiology

Date 2013 Jan 10

PMID 23300040

Citations 8

Authors

Sung Ho Hwang

Mi Ri Yoo

Chul Hwan Park

Tae Joo Jeon

Sang Jin Kim

Tae Hoon Kim

Affiliations

Soon will be listed here.

Abstract

Objectives: To compare tumour enhancement patterns measured using dynamic contrast-enhanced (DCE)-CT with tumour metabolism measured using positron emission tomography (PET)-CT in patients with non-small cell lung cancer (NSCLC) and stable disease after chemotherapy or chemoradiotherapy.

Methods: After treatment, 75 NSCLC tumours in 65 patients who had stable disease on DCE-CT according to Response Evaluation Criteria in Solid Tumour (RECIST) were evaluated using PET-CT. On DCE-CT, relative enhancement ratios (RER) of tumour at 30, 60, 90, 120 s and 5 min after injection of contrast material were measured. Metabolic responses of tumours were classified into two groups according to the maximum standardized uptake value (SUVmax) by PET-CT: complete metabolic response (CR) with an SUVmax of less than 2.5, and noncomplete metabolic response (NR) with an SUVmax of at least 2.5.

Results: Using the optimal RER₆₀ cutoff value of 43.7 % to predict NR of tumour gave 95.7 % sensitivity, 64.2 % specificity, and 82.1 % positive and 95.0 % negative predictive values. After adjusting for tumour size, the odds ratio for NR in tumour with an RER60 of at least 43.7 % was 70.85 (95 % CI = 7.95-630.91; P < 0.05).

Conclusions: Even when disease was stable according to RECIST, DCE-CT predicted hypermetabolic status of residual tumour in patients with NSCLC after treatment.

Key Points: • Dynamic contrast-enhanced CT (DCE-CT) can provide useful metabolic information about non-small cell lung cancer. • NSCLC lesions, even grossly stable after treatment, show various metabolic states. • DCE-CT enhancement patterns correlate with tumour metabolic status as shown by PET. • DCE-CT helps to assess hypermetabolic NSCLC as stable disease after treatment.

Citing Articles

Improving radiation physics, tumor visualisation, and treatment quantification in radiotherapy with spectral or dual-energy CT.

Kruis M J Appl Clin Med Phys. 2021; 23(1):e13468.

PMID: 34743405 PMC: 8803285. DOI: 10.1002/acm2.13468.

Imaging for Response Assessment in Radiation Oncology: Current and Emerging Techniques.

Stieb S, Kiser K, van Dijk L, Livingstone N, Elhalawani H, Elgohari B Hematol Oncol Clin North Am. 2019; 34(1):293-306.

PMID: 31739950 PMC: 7253297. DOI: 10.1016/j.hoc.2019.09.010.

Dynamic Contrast-enhanced Area-detector CT vs Dynamic Contrast-enhanced Perfusion MRI vs FDG-PET/CT: Comparison of Utility for Quantitative Therapeutic Outcome Prediction for NSCLC Patients Undergoing Chemoradiotherapy.

Seki S, Fujisawa Y, Yui M, Kishida Y, Koyama H, Ohyu S Magn Reson Med Sci. 2019; 19(1):29-39.

PMID: 30880291 PMC: 7067914. DOI: 10.2463/mrms.mp.2018-0158.

CT perfusion imaging of lung cancer: benefit of motion correction for blood flow estimates.

Chu L, Knebel R, Shay A, Santos J, Badawi R, Gandara D Eur Radiol. 2018; 28(12):5069-5075.

PMID: 29869174 DOI: 10.1007/s00330-018-5492-1.

CT imaging features associated with recurrence in non-small cell lung cancer patients after stereotactic body radiotherapy.

Li Q, Kim J, Balagurunathan Y, Qi J, Liu Y, Latifi K Radiat Oncol. 2017; 12(1):158.

PMID: 28946909 PMC: 5613447. DOI: 10.1186/s13014-017-0892-y.

References

Bellomi M, Petralia G, Sonzogni A, Giulia Zampino M, Rocca A . CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology. 2007; 244(2):486-93. DOI: 10.1148/radiol.2442061189. View

Tran L, Brown M, Goldin J, Yan X, Pais R, McNitt-Gray M . Comparison of treatment response classifications between unidimensional, bidimensional, and volumetric measurements of metastatic lung lesions on chest computed tomography. Acad Radiol. 2004; 11(12):1355-60. DOI: 10.1016/j.acra.2004.09.004. View

Suzuki C, Jacobsson H, Hatschek T, Torkzad M, Boden K, Eriksson-Alm Y . Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics. 2008; 28(2):329-44. DOI: 10.1148/rg.282075068. View

Dean P, Niemi P, Kivisaari L, Kormano M . Comparative pharmacokinetics of gadolinium DTPA and gadolinium chloride. Invest Radiol. 1988; 23 Suppl 1:S258-60. DOI: 10.1097/00004424-198809001-00055. View

Pezzella F, Pastorino U, Tagliabue E, Andreola S, Sozzi G, Gasparini G . Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol. 1997; 151(5):1417-23. PMC: 1858069. View

Patz Jr E, Connolly J, Herndon J . Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR Am J Roentgenol. 2000; 174(3):769-74. DOI: 10.2214/ajr.174.3.1740769. View

Huang W, Zhou T, Ma L, Sun H, Gong H, Wang J . Standard uptake value and metabolic tumor volume of ¹⁸F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011; 38(9):1628-35. DOI: 10.1007/s00259-011-1838-5. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T . Cancer statistics, 2008. CA Cancer J Clin. 2008; 58(2):71-96. DOI: 10.3322/CA.2007.0010. View

Alberg A, Ford J, Samet J . Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132(3 Suppl):29S-55S. DOI: 10.1378/chest.07-1347. View

10.

Mazumdar M, Smith A, Schwartz L . A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epidemiol. 2004; 57(4):358-65. DOI: 10.1016/j.jclinepi.2003.07.015. View

11.

Juweid M, Cheson B . Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006; 354(5):496-507. DOI: 10.1056/NEJMra050276. View

12.

Cuenod C, Fournier L, Balvay D, Guinebretiere J . Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment. Abdom Imaging. 2006; 31(2):188-93. DOI: 10.1007/s00261-005-0386-5. View

13.

Decoster L, Schallier D, Everaert H, Nieboer K, Meysman M, Neyns B . Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2008; 62(1):55-61. DOI: 10.1016/j.lungcan.2008.02.015. View

14.

Weidner N, Semple J, Welch W, Folkman J . Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991; 324(1):1-8. DOI: 10.1056/NEJM199101033240101. View

15.

Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma A . Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 2000; 35(13):1773-82. DOI: 10.1016/s0959-8049(99)00229-4. View

16.

Schaefer J, Vollmar J, Schick F, Vonthein R, Seemann M, Aebert H . Solitary pulmonary nodules: dynamic contrast-enhanced MR imaging--perfusion differences in malignant and benign lesions. Radiology. 2004; 232(2):544-53. DOI: 10.1148/radiol.2322030515. View

17.

Swensen S, Viggiano R, Midthun D, Muller N, Sherrick A, Yamashita K . Lung nodule enhancement at CT: multicenter study. Radiology. 2000; 214(1):73-80. DOI: 10.1148/radiology.214.1.r00ja1473. View

18.

Watanabe H, Yamamoto S, Kunitoh H, Sekine I, Yamamoto N, Ohe Y . Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients. Cancer Sci. 2003; 94(11):1015-20. PMC: 11160149. DOI: 10.1111/j.1349-7006.2003.tb01394.x. View

19.

Erasmus J, Gladish G, Broemeling L, Sabloff B, Truong M, Herbst R . Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol. 2003; 21(13):2574-82. DOI: 10.1200/JCO.2003.01.144. View

20.

Laskin J, Sandler A . State of the art in therapy for non-small cell lung cancer. Cancer Invest. 2005; 23(5):427-42. DOI: 10.1081/cnv-67172. View